Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Post-Marketing Surveillance to Evaluate the Safety and Effectiveness of Mirvetuximab Soravtansine-gynx in Patients With Folate Receptor-Alpha Positive, Platinum-Resistant, High-grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT07687602 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT07687602
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07687602 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Post-Marketing Surveillance to Evaluate the Safety and Effectiveness of Mirvetuximab Soravtansine-gynx in Patients With Folate Receptor-Alpha Positive, Platinum-Resistant, High-grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Lead sponsor
AbbVie
Phase
Observational
Overall status
Not yet recruiting
Start date
June 30, 2026
Completion date
August 31, 2031
Enrollment
69 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

folate receptor-alpha positive platinum-resistant fallopian tube cancer, folate receptor-alpha positive platinum-resistant high-grade serous epithelial ovarian cancer, folate receptor-alpha positive platinum-resistant primary peritoneal cancer